Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 14Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Unresectable Hepatocellular Carcinoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrent Squamous Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Non-Small Cell Lung Cancer NSCLC 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Hepatobiliary Cancers 1Head and Neck Neoplasms 1Deglutition Disorders 1

Interventions

Blood Specimen Collection 14Nivolumab 13Ipilimumab 12pembrolizumab 11trametinib 9Surveys and Questionnaires 9Gene Expression Profiling 9dabrafenib 8Biopsy 6Specimen Handling 5Immunotherapy 5Immunohistochemistry 5Amplified Fragment Length Polymorphism Analysis 4encorafenib 3binimetinib 3atezolizumab 3Restraint, Physical 3Quality of Life 3Polymerase Chain Reaction 3Introns 3Flow Cytometry 3Drug Therapy 3Data Collection 3tremelimumab 2pimonidazole 2cobimetinib 2aldesleukin 2Watchful Waiting 2Vemurafenib 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Melanoma × durvalumab × Clear all
NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Cambridge University Hospitals NHS Foundation Trust

Unknown
1,800 enrolled
DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡